**We Claim:**

**1.** A compound of Formula (I), or a pharmaceutically acceptable salt thereof:



(I)

wherein:

each of $R^a$ and $R^b$ is independently H or $C_{1-3}$alkyl;

$R^1$ is H, OH, $C_{1-3}$alkyl, $OC_{1-3}$alkyl, $=CH_2$, or $=NOR^5$; or $R^1$ is $C_{3-6}$cycloalkyl or $C_{3-6}$heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached;

each of $R^{1a}$ and $R^{1b}$ is independently H or $C_{1-3}$ alkyl;

$R^2$ is $C_{3-9}$heterocycloalkyl or $C_{3-9}$heterocycloalkenyl, or $R^2$ is selected from the group consisting of  ,  , and  , and $R^6$ is $C_{1-6}$alkyl, $C_{3-8}$cycloalkyl, or $C_{6-10}$aryl, or $R^2$ is selected from the group consisting of 





$R^3$ is $C_{3-8}$cycloalkyl, $C_{3-8}$cycloalkenyl, $C_{3-7}$heterocycloalkyl, or $C_{2-6}$heteroaryl;

$R^4$ is $C_{6-10}$aryl or $C_{2-6}$heteroaryl, and $R^4$ is optionally substituted with one to three groups independently selected from halo, $C_{1-3}$alkyl, $C_{1-3}$alkoxy, $C(O)N(R^N)_2$, and $N(R^N)_2$, and each $R^N$ is independently H or $C_{1-3}$alkyl;

each $R^5$ independently is H, $C_{1-3}$alkyl, or $C_{0-2}$alkylene-$C_{6-10}$aryl;

X is $C_{1-3}$alkylene;

Y is SO or $SO_2$; and

each heterocycloalkyl, heterocycloalkenyl, and heteroaryl group independently has 1, 2, or 3 ring heteroatoms selected from N, O, and S.

**2.** The compound or salt of claim 1, wherein each Y is SO.

**3.** The compound or salt of claim 1, wherein each Y is $SO_2$.

**4.** The compound or salt of any one of claims 1-3, wherein $R^a$ is H.

**5.** The compound or salt of any one of claims 1-3, wherein $R^a$ is $C_{1-3}$alkyl.

**6.** The compound or salt of claim 5, wherein $R^a$ is $CH_3$.

**7.** The compound or salt of any one of claims 1-6, wherein $R^b$ is H.

**8.** The compound or salt of any one of claims 1-6, wherein $R^b$ is $C_{1-3}$alkyl.

**9.** The compound or salt of claim 8, wherein $R^a$ is $CH_3$.

**10.** The compound or salt of any one of claims 1-9, wherein $R^1$ is H, OH, or $=NOR^5$.

**11.** The compound or salt of claim 10, wherein $R^5$ is H or $CH_3$.

**12.** The compound or salt of any one of claims 1-9, wherein $R^1$ is $C_{1-3}$alkyl or $OC_{1-3}$alkyl.

**13.** The compound or salt of claim 12, wherein $R^1$ is $CH_3$ or $OCH_3$.

**14.** The compound or salt of claim 13, wherein $R^1$ is $CH_3$ and exhibits *S* stereochemistry.

**15.** The compound or salt of any one of claims 1-9, wherein $R^1$ is $C_{3-6}$cycloalkyl or $C_{3-6}$heterocycloalkyl and forms a spiro group with the ring carbon to which it is attached.

**16.** The compound or salt of claim 15, wherein $R^1$ together with the ring atom to which it is attached forms  ,  , or  .

**17.** The compound or salt of any one of claims 1-9, wherein $R^1$ is $=CH_2$.

**18.** The compound or salt of any one of claims 1-17, wherein each of $R^{1a}$ and $R^{1b}$ is H.

**19.** The compound or salt of any one of claims 1-17, wherein at least one of of $R^{1a}$ and $R^{1b}$ is $C_{1\text{-}3}$alkyl.

**20.** The compound or salt of claim 19, wherein each of $R^{1a}$ and $R^{1b}$ is $CH_3$.

**21.** The compound or salt of any one of claims 1-20, wherein $R^2$ comprises oxetanyl, azetidinyl, tetrahydrofuranyl, pyrrolidinyl, tetrahydropyranyl, pyranyl, piperidinyl, piperazinyl, azepanyl, or tetrahydropyridinyl.

**22.** The compound or salt of claim 1, wherein $R^2$ is selected from the group consisting of  ,  , and  , and $R^6$ is $C_{1\text{-}6}$alkyl, $C_{3\text{-}8}$cycloalkyl, or $C_{6\text{-}10}$aryl.

**23.** The compound or salt of claim 22, wherein $R^6$ is phenyl optionally substituted with one to three groups independently selected from halo, $C_{1\text{-}3}$alkyl, $C_{1\text{-}3}$alkoxy, and CN.

**24.** The compound or salt of claim 1, wherein $R^2$ is selected from the group consisting of





 ,  ,  ,

 ,  ,  ,  ,

 ,  ,  ,  ,

 ,  ,  ,

 ,  ,  ,  ,  ,

 , and  .

**25.** The compound or salt of claim 24, wherein $R^2$ is selected from the group consisting of  ,  ,  ,  ,

 ,  ,  ,

 , and  .

**26.** The compound or salt of any one of claims 1-25, wherein X is $CH_2$, $CH_2CH_2$, or $CH(CH_3)$.

**27.** The compound or salt of any one of claims 1-26, wherein $R^3$ comprises cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl, cyclohexenyl,

tetrahydropyranyl, pyrrolyl, pyrazolyl, imidazolyl, tetrazolyl, furanyl, thiophenyl, thiazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiadiazolyl, pyridinyl, pyrazinyl, or pyrimidinyl.

**28.** The compound or salt of claim 26, wherein X-$R^3$ is selected from the group consisting of  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , ,  , , and .

**29.** The compound or salt of claim 28, wherein X-$R^3$ is , , , or .

**30.** The compound or salt of claim 29, wherein X-$R^3$ is , or .

**31.** The compound or salt of any one of claims 1-30, wherein $R^4$ comprises $C_{3\text{-}8}$cycloalkyl or $C_{3\text{-}9}$heterocycloalkyl.

**32.** The compound or salt of claim 31, wherein $R^4$ is  or .

**33.** The compound or salt of any one of claims 1-32, wherein $R^4$ is substituted with one to three groups independently selected from halo, $C_{1\text{-}3}$alkyl, $C_{1\text{-}3}$alkoxy, $C(O)N(R^N)_2$, and $N(R^N)_2$, and each $R^N$ is independently H or $C_{1\text{-}3}$alkyl.

**34.** The compound or salt of claim 1, wherein $R^4$ is selected from the group consisting of  ,  ,  , and .

**35.** The compound or salt of claim 34, wherein $R^4$ is  .

**36.** The compound or salt of claim 1, wherein:

$R^a$, $R^b$, $R^{1a}$, and $R^{1b}$ are each H;

$R^1$ is $=CH_2$ or $CH_3$;

$R^2$ is  ;

$X\text{-}R^3$ is  ;

$R^4$ is  ; and

each Y is $SO_2$.

**37.** The compound or salt of any one of claims 1-36, wherein $R^1$ is in a *(S)* configuration.

**38.** A compound listed in Table A, or a pharmaceutically acceptable salt thereof.

| No. | Structure |
|---|---|
| A5 |  |
| A13 |  |
| A17 |  |
| A19 |  |
| A20 |  |
| A21 |  |
| A22 |  |
| A23 |  |
| A24 |  |
| A25 |  |

| | |
|---|---|
| A26 |  |
| A27 |  |
| A28 |  |
| A29 |  |
| A30 |  |
| A31 |  |

| | |
|---|---|
| A32 |  |
| A33 |  |
| A34 |  |
| A35 |  |
| A36 |  |
| A37 |  |

| | |
|---|---|
| A38 |  |
| A39 |  |
| A40 |  |
| A41 |  |
| A42 |  |
| A43 |  |

| | |
|---|---|
| A44 |  |
| A46 |  |
| A47 |  |
| A48 |  |
| A49 |  |
| A50 |  |

| | |
|---|---|
| A51 |  |
| A52 |  |
| A53 |  |
| A54 |  |
| A55 |  |
| A56 |  |

| | |
|---|---|
| A57 |  |
| A58 |  |
| A59 |  |
| A60 |  |
| A61 |  |

| | |
|---|---|
| A63 |  |
| A64 |  |
| A65 |  |
| A66 |  |
| A67 |  |
| A68 |  |

| | |
|---|---|
| A69 |  |
| A70 |  |
| A71 |  |
| A72 |  |
| A73 |  |
| A74 |  |

| | |
|---|---|
| A75 |  |
| A76 |  |
| A77 |  |
| A78 |  |
| A79 |  |
| A80 |  |

| | |
|---|---|
| A81 |  |
| A82 |  |
| A83 |  |
| A84 |  |
| A85 |  |
| A86 |  |

| | |
|---|---|
| A87 |  |
| A88 |  |
| A89 |  |
| A90 |  |
| A91 |  |

| | |
|---|---|
| A92 |  |
| A93 |  |
| A94 |  |
| A95 |  |
| A96 |  |

| | |
|---|---|
| A97 |  |
| A98 |  |
| A99 |  |
| A100 |  |
| A101 |  |

| | |
|---|---|
| A102 |  |
| A104 |  |
| A108 |  |
| A109 |  |
| A110 |  |

| | |
|---|---|
| A111 |  |
| A112 |  |
| A113 |  |
| A114 |  |

| | |
|---|---|
| A115 |  |
| A116 |  |
| A117 |  |
| A118 |  |

| | |
|---|---|
| A119 |  |
| A120 |  |
| A121 |  |
| A122 |  |
| A123 |  |
| A124 |  |

| | |
|---|---|
| A125 |  |
| A126 |  |
| A127 |  |
| A128 |  |
| A129 |  |
| A130 |  |

| | |
|---|---|
| A134 |  |
| A135 |  |
| A136 |  |
| A137 |  |
| A138 |  |
| A142 |  |

| | |
|---|---|
| A143 |  |
| A144 |  |
| A145 |  |
| A146 |  |
| A147 |  |
| A148 |  |

| | |
|---|---|
| A149 |  |
| A150 |  |
| A151 |  |
| A153 |  |
| A154 |  |

| | |
|---|---|
| A155 |  |
| A157 |  |
| A160 |  |
| A161 |  |
| A162 |  |

| | |
|---|---|
| A163 |  |
| A164 |  |
| A166 |  |
| A168 |  |
| A169 |  |
| A170 |  |

| | |
|---|---|
| A171 |  |
| A172 |  |
| A173 |  |
| A174 |  |
| A175 |  |

| | |
|---|---|
| A176 |  |
| A177 |  |
| A178 |  |
| A179 |  |
| A180 |  |
| A181 |  |

| | |
|---|---|
| A182 |  |
| A183 |  |
| A185 |  |
| A188 |  |
| A190 |  |
| A191 |  |

| | |
|---|---|
| A193 |  |
| A194 |  |
| A195 |  |
| A196 |  |
| A197 |  |

| | |
|---|---|
| A198 |  |
| A199 |  |
| A200 |  |
| A201 |  |
| A202 |  |

| | |
|---|---|
| A203 |  |
| A204 |  |
| A206 |  |
| A207 |  |
| A208 |  |

| | |
|---|---|
| A209 |  |
| A210 |  |

**39.** The compound or salt of claim 38, wherein the compound is selected from the group consisting of:


,

,

,

,

,

,


,

,

, and

.

**40.** A pharmaceutical composition comprising the compound or salt of any one of claims 1-39 and a pharmaceutically acceptable carrier.

**41.** The compound or salt of any one of claims 1-39, or the pharmaceutical composition of claim 40, for use as a treatment of cancer.

**42.** The compound or salt of any one of claims 1-39, or the pharmaceutical composition of claim 40, for use as a medicament.

**43.** Use of the compound or salt of any one of claims 1-39 or the pharmaceutical composition of claim 40, in the manufacture of a medicament for treating inflammation in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

**44.** Use of the compound or salt of any one of claims 1-39 or the pharmaceutical composition of claim 40, in the manufacture of a medicament for treating or preventing cancer or a precancerous condition in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

**45.** The use of claim 44, wherein the cancer is melanoma, multiple myeloma, prostate cancer, lung cancer, pancreatic cancer, squamous cell carcinoma, leukemia, lymphoma, a neuroendocrine tumor, bladder cancer, or colorectal cancer.

**46.** The use of claim 44, wherein the cancer is non small cell lung carcinoma, squamous cell carcinoma, leukemia, acute myelogenous leukemia, chronic myelogenous leukemia, lymphoma, NPM/ALK-transformed anaplastic large cell lymphoma, diffuse large B cell lymphoma, neuroendocrine tumors, breast cancer, mantle cell lymphoma, renal cell carcinoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, small cell carcinoma, adenocarcinoma, gastric carcinoma, hepatocellular carcinoma, pancreatic cancer, thyroid carcinoma, anaplastic large cell lymphoma, hemangioma, or head and neck cancer.

**47.** The use of claim 44, wherein the cancer is a solid tumor.

**48.** The use of claim 44, wherein the cancer is head and neck cancer, squamous cell carcinoma, gastric carcinoma, or pancreatic cancer.

**49.** Use of the compound or salt of any one of claims 1-39 or the pharmaceutical composition of claim 40, in the manufacture of a medicament for treating an autoimmune disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

**50.** The use of claim 49, wherein the autoimmune disease is psoriasis, dermatitis, systemic scleroderma, sclerosis, Crohn’s disease, ulcerative colitis; respiratory distress syndrome, meningitis; encephalitis; uveitis; colitis; glomerulonephritis; eczema, asthma, chronic inflammation; atherosclerosis; leukocyte adhesion deficiency; rheumatoid arthritis; systemic lupus erythematosus (SLE); diabetes mellitus; multiple sclerosis; Reynaud’s syndrome; autoimmune thyroiditis; allergic encephalomyelitis; Sjorgen’s syndrome; juvenile onset diabetes; tuberculosis, sarcoidosis, polymyositis, granulomatosis and vasculitis; pernicious anemia (Addison’s disease); diseases involving leukocyte diapedesis; central nervous system (CNS) inflammatory disorder; multiple organ injury syndrome; hemolytic anemia; myasthenia gravis; antigen-antibody complex mediated diseases; anti-glomerular basement membrane disease; antiphospholipid syndrome; allergic neuritis; Graves’ disease; Lambert-Eaton myasthenic syndrome; pemphigoid bullous; pemphigus;

autoimmune polyendocrinopathies; Reiter's disease; stiff-man syndrome; Behcet disease; giant cell arteritis; immune complex nephritis; IgA nephropathy; IgM polyneuropathies; immune thrombocytopenic purpura (ITP) or autoimmune thrombocytopenia.

**51.** Use of the compound or salt of any one of claims 1-39 or the pharmaceutical composition of claim 40, in the manufacture of a medicament for the treatment of an immune-related disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

**52.** The use of claim 51, wherein the immune-related disease is rheumatoid arthritis, lupus, inflammatory bowel disease, multiple sclerosis, or Crohn's disease.

**53.** Use of the compound or salt of any one of claims 1-39 or the pharmaceutical composition of claim 40, in the manufacture of a medicament for treating neurodegenerative disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

**54.** The use of claim 53, wherein the neurodegenerative disease is multiple sclerosis.

**55.** Use of the compound or salt of any one of claims 1-39 or the pharmaceutical composition of claim 40, in the manufacture of a medicament for treating an inflammatory disease in a subject, wherein a therapeutically effective amount of the medicament is to be administered to the subject.

**56.** The use of claim 55, wherein the inflammatory disease is bronchitis, conjunctivitis, myocarditis, pancreatitis, chronic cholecstitis, bronchiectasis, aortic valve stenosis, restenosis, psoriasis or arthritis.